Drugs / PD1-PSMA-CART cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04768608 | Dec 2021 → Jun 2022 | castration-resistant prostate carcinoma | Zhejiang University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD1-PSMA-CART cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04768608 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T(CART) cells” NCT04768608 ↗ |
| Route | Intravenous | “PD1-PSMA-CART cells will be given IV at split doses” NCT04768608 ↗ |